XTX Topco Ltd Trims Holdings in Doximity, Inc. (NASDAQ:DOCS)

XTX Topco Ltd lessened its stake in Doximity, Inc. (NASDAQ:DOCSFree Report) by 53.2% in the 3rd quarter, Holdings Channel reports. The firm owned 12,988 shares of the company’s stock after selling 14,782 shares during the period. XTX Topco Ltd’s holdings in Doximity were worth $566,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC lifted its position in shares of Doximity by 324.2% during the third quarter. Farther Finance Advisors LLC now owns 789 shares of the company’s stock worth $34,000 after purchasing an additional 603 shares in the last quarter. Blue Trust Inc. increased its stake in Doximity by 621.4% during the 2nd quarter. Blue Trust Inc. now owns 1,385 shares of the company’s stock worth $37,000 after buying an additional 1,193 shares during the period. Quarry LP lifted its holdings in Doximity by 101.2% during the 2nd quarter. Quarry LP now owns 1,616 shares of the company’s stock worth $45,000 after buying an additional 131,253 shares in the last quarter. Morse Asset Management Inc purchased a new position in Doximity in the 3rd quarter valued at approximately $46,000. Finally, First Horizon Advisors Inc. grew its stake in shares of Doximity by 80.0% in the second quarter. First Horizon Advisors Inc. now owns 1,710 shares of the company’s stock worth $48,000 after acquiring an additional 760 shares in the last quarter. Hedge funds and other institutional investors own 87.19% of the company’s stock.

Doximity Stock Performance

Doximity stock opened at $52.14 on Friday. The company has a market capitalization of $9.73 billion, a P/E ratio of 59.93, a PEG ratio of 4.16 and a beta of 1.40. Doximity, Inc. has a fifty-two week low of $22.96 and a fifty-two week high of $61.75. The stock has a 50-day simple moving average of $48.05 and a 200-day simple moving average of $37.88.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the company. Wells Fargo & Company upgraded Doximity from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $19.00 to $41.00 in a research note on Friday, November 8th. Barclays lifted their price objective on Doximity from $52.00 to $75.00 and gave the company an “overweight” rating in a research note on Monday, November 11th. Robert W. Baird upped their target price on shares of Doximity from $41.00 to $45.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. Bank of America lifted their price target on shares of Doximity from $32.00 to $45.00 and gave the stock a “neutral” rating in a research note on Monday, October 7th. Finally, Raymond James reissued an “outperform” rating and issued a $65.00 price objective (up from $37.00) on shares of Doximity in a research report on Friday, November 8th. Twelve investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Doximity has a consensus rating of “Hold” and a consensus target price of $52.44.

Read Our Latest Report on DOCS

About Doximity

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Further Reading

Want to see what other hedge funds are holding DOCS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Doximity, Inc. (NASDAQ:DOCSFree Report).

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.